Targeting platelets for prevention and treatment of cardiovascular disease

被引:23
作者
Duhamel, Todd A. [1 ]
Xu, Yan-Jun [1 ]
Arneja, Amarjit S. [2 ]
Dhalla, Naranjan S. [1 ]
机构
[1] Univ Manitoba, Fac Med, Dept Physiol, St Boniface Gen Hosp Res Ctr,Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada
[2] Univ Manitoba, St Boniface Gen Hosp Res Ctr, Dept Internal Med, Inst Cardiovasc Sci,Fac Med, Winnipeg, MB, Canada
基金
加拿大健康研究院;
关键词
cardiovascular diseases; natural food products; nutraceutical interventions; pharmacologic interventions; platelet aggregation and adhesion; prevention; therapy;
D O I
10.1517/14728222.11.12.1523
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platelets play an important role in the development of thrombosis, atherosclerosis, hypertension, heart attack and stroke. As a result, pharmacologic interventions that influence platelet functions, such as adhesion, aggregation and the release of different factors, are considered useful for the prevention and treatment of cardiovascular disease. Although classical anti-platelet agents have proven beneficial effects for the treatment of some specific cardiovascular diseases, there are limitations for their use as these drugs target platelet function directly. In contrast, newly developed anti-platelet agents have broad applications for the treatment of cardiovascular disease as they not only influence platelet function but are also considered to affect cardiac and vascular smooth muscle cell functions. Natural food products and nutraceutical agents also appear to modify cardiovascular abnormalities by affecting various platelet functions; however the mechanisms of their actions remain to be investigated. Accordingly, this article is focused to discuss emerging pharmacologic, nutritional and nutraceutical interventions that may influence the prevention or progression of a broad range of cardiovascular diseases.
引用
收藏
页码:1523 / 1533
页数:11
相关论文
共 103 条
[71]  
Sharma SK, 1999, J PHARMACOL EXP THER, V290, P1475
[72]   Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: Implications for long-term graft patency [J].
Sharma, SK ;
Del Rizzo, DF ;
Zahradka, P ;
Bhangu, SK ;
Werner, JP ;
Kumamoto, H ;
Takeda, N ;
Dhalla, NS .
ANNALS OF THORACIC SURGERY, 2001, 71 (06) :1856-1864
[73]  
Shen Lianzhong, 1998, Zhongguo Zhongyao Zazhi, V23, P622
[74]  
Solberg Ole Geir, 2007, Tidsskr Nor Laegeforen, V127, P179
[75]  
Streefkerk J. O., 2006, Autonomic & Autacoid Pharmacology, V26, P141, DOI 10.1111/j.1474-8673.2006.00361.x
[76]   Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery [J].
Tangelder, MJD ;
Lawson, JA ;
Algra, A ;
Eikelboom, BC .
JOURNAL OF VASCULAR SURGERY, 1999, 30 (04) :701-709
[77]   Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart [J].
Temsah, RM ;
Kumamoto, H ;
Takeda, N ;
Dhalla, NS .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (09) :761-767
[78]   BLOOD-PLATELET COUNT AND FUNCTION ARE RELATED TO TOTAL AND CARDIOVASCULAR DEATH IN APPARENTLY HEALTHY-MEN [J].
THAULOW, E ;
ERIKSSEN, J ;
SANDVIK, L ;
STORMORKEN, H ;
COHN, PF .
CIRCULATION, 1991, 84 (02) :613-617
[79]   Effects of the nonpeptide V1 vasopressin receptor antagonist SR49059 in hypertensive patients [J].
Thibonnier, M ;
Kilani, A ;
Rahman, M ;
DiBlasi, TP ;
Warner, K ;
Smith, MC ;
Leenhardt, AF ;
Brouard, R .
HYPERTENSION, 1999, 34 (06) :1293-1300
[80]   The use of ginger (Zingiber officinale Rosc.) as a potential antiminflammatory and antithrombotic agent [J].
Thomson, M ;
Al-Qattan, KK ;
Al-Sawan, SM ;
Alnaqeeb, MA ;
Khan, I ;
Ali, M .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2002, 67 (06) :475-478